A revival in AstraZeneca Plc shares faces a key test this week, with more likely to hinge on the drugmaker’s ability to ...

Q3 2024 Management View Revenue for Q3 FY2024 increased 16.6% year-on-year to ¥1,367.6 billion, driven by growth in oncology ...

Big Pharma often turns to NFL games to hawk their blockbuster treatments, but drug makers have typically been hesitant to ...

Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief ...

Tokyo: Daiichi Sankyo Company, Ltd has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive ...

Robert F. Kennedy Jr. may soon be America's top pharmaceutical regulator. That is cause for concern in Seattle’s biotech ...

U.S. President Donald Trump plans to impose tariffs on imported computer chips, pharmaceuticals and steel, he said on Monday, ...

Japanese drugmaker Daiichi Sankyo has appointed Hiroyuki Okuzawa to succeed Sunao Manabe, as chief executive (CEO), effective ...

Japanese healthcare firm Daiichi Sankyo Co., Ltd (DSKYF.PK) announced Friday the appointment of Hiroyuki Okuzawa as Chief Executive ...

TOKYO--(BUSINESS WIRE)--Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO), effective April 1 ...

AstraZeneca (AZN) stock in focus as its partner Daiichi Sankyo (DSNKY) wins EU backing for their jointly developed breast ...

That includes the recent decision to reject NHS use of AZ and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) for HER2-low ...